Zentalis Pharmaceuticals, Inc. - 10-Q Filing

Zentalis Pharmaceuticals reports Q3 2026 financial results with 98.3 million shares outstanding as of November 4, 2026.

SEC EDGAR ·

Tickers: $ZNTL

Read the full article at SEC EDGAR

More Regulatory news